Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate |
2018-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ffd110e00222c6d9f207188abb0ebc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57ac156e575ef60398c29ff324dfc7c6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fd57c007951d59af3a186b00b8bfe69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58b41b54cb960a8ac54dbaa65c7506a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87e3da5b239663985d94cc0d8f85ad43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dbe6e8046da42e3d8d88f7ac2dd091b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ddfc96670df49a30e6bd81e8190553c |
publicationDate |
2020-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20200064132-A |
titleOfInvention |
How to treat a tumor |
abstract |
The disclosure discloses monotherapy or anti-PD-1 antibodies and anti-CTLA-comprising anti-PD-1 antibodies to subjects suffering from tumors derived from small cell lung cancer (SCLC) with high tumor mutation burden (TMB) status. Provided is a method of treating a subject suffering from a tumor derived from small cell lung cancer (SCLC) with high tumor mutation burden (TMB) status, comprising administering a combination therapy comprising 4 antibodies. The present disclosure is also suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody, comprising measuring the TMB status of a biological sample of a subject. Provides a method for identifying a subject. The high TMB status confirms that the patient is suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. TMB status can be determined by sequencing nucleic acids in a tumor and identifying genomic alterations, such as mutations in somatic sinuses, in the sequenced nucleic acids. |
priorityDate |
2017-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |